Payment overview · 2025
General Payments
$243.06
13 reported records · 6 companies
Healthcare provider profile · identity verified
David Hyman Bresticker, MD
Allopathic & Osteopathic Physicians|Family Medicine · WILLIAMSPORT, PA · NPI 1376582841
Verified facts
What the public records show
CMS Open Payments records show David Hyman Bresticker, MD received $243.06 in general payments during 2025 across 13 reported records.
ABBVIE INC. accounted for 50.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $122.34 | 50.3% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.88 | 16.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.24 | 13.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.05 | 7.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.99 | 6.6% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $13.56 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $227.07 | 12 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.38 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.80 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $39.88 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.26 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 937 | 240 |
| Amlodipine Besylate | Amlodipine Besylate | 818 | 176 |
| Lisinopril | Lisinopril | 462 | 114 |
| Omeprazole | Omeprazole | 444 | 111 |
| Hydrochlorothiazide | Hydrochlorothiazide | 392 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 380 | 91 |
| Metformin Hcl | Metformin Hcl | 316 | 66 |
| Gabapentin | Gabapentin | 281 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 73 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 275 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 68 |
| Furosemide | Furosemide | 248 | 64 |
| Eliquis | Apixaban | 226 | 41 |
| Losartan Potassium | Losartan Potassium | 226 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 221 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 202 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 44 |
| Meloxicam | Meloxicam | 186 | 51 |
| Lorazepam | Lorazepam | 185 | 49 |
| Trazodone Hcl | Trazodone Hcl | 170 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 36 |
| Sertraline Hcl | Sertraline Hcl | 167 | 30 |
| Jardiance | Empagliflozin | 164 | 28 |
| Metformin Hcl Er | Metformin Hcl | 163 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 162 | 40 |
| Tramadol Hcl | Tramadol Hcl | 153 | 32 |
| Potassium Chloride | Potassium Chloride | 149 | 40 |
| Simvastatin | Simvastatin | 148 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 25 |
| Prednisone | Prednisone | 145 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 60 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 127 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 25 |
| Famotidine | Famotidine | 113 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 22 |
| Ozempic | Semaglutide | 104 | 16 |
| Pregabalin | Pregabalin | 98 | 18 |
| Alendronate Sodium | Alendronate Sodium | 97 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 17 |
| Buspirone Hcl | Buspirone Hcl | 92 | 15 |
| Celecoxib | Celecoxib | 90 | 18 |
| Carvedilol | Carvedilol | 89 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 23 |
| Aripiprazole | Aripiprazole | 86 | 12 |
| Alprazolam | Alprazolam | 83 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 80 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 78 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 14 |
| Finasteride | Finasteride | 77 | 21 |
| Glipizide Er | Glipizide | 74 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 21 |
| Donepezil Hcl | Donepezil Hcl | 64 | suppressed |
| Clonazepam | Clonazepam | 61 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 15 |
| Allopurinol | Allopurinol | 59 | 14 |
| Montelukast Sodium | Montelukast Sodium | 59 | 13 |
| Myrbetriq | Mirabegron | 54 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Trulicity | Dulaglutide | 53 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 35 |
| Ezetimibe | Ezetimibe | 48 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 16 |
| Atenolol | Atenolol | 46 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 43 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 45 | suppressed |
| Spironolactone | Spironolactone | 45 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | suppressed |
| Tradjenta | Linagliptin | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Glimepiride | Glimepiride | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 11 |
| Ketoconazole | Ketoconazole | 38 | 25 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 38 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Cephalexin | Cephalexin | 34 | 18 |
| Valsartan | Valsartan | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 31 | 17 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Mirtazapine | Mirtazapine | 29 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 22 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 15 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | 12 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Norgestimate-Ethinyl Estradiol | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Methazolamide | Methazolamide | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.06 · 13 records | ABBVIE INC. | AREXVY, BREZTRI, BRIXADI, CREON, EVENITY, GEMTESA, QULIPTA, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error